Shots:

• AstraZeneca has expanded the development of AZD1222 into P-III D8110C00001 study to assess its safety- efficacy- and immunogenicity. BARDA has funded the P-III study to accelerate the development of the vaccine
• The P-III D8110C00001 study involves assessing of AZD1222 vs PBO for the prevention of COVID-19- in up to 30-000 participants aged ≥ 18yrs. in a ratio (2:1) across ~100 trial centers in and outside the US. Participants are being randomized to receive two doses of either AZD1222 or saline control- 4wks. apart- with twice as many participants receiving the potential vaccine than the saline control
• The company is evaluating the AZD1222 globally with late-stage clinical trials ongoing in the UK- Brazil- and South Africa- while the trials are planned to start in Japan and Russia

­ Ref: AstraZeneca | Image: Deccan Herald